The treatment of refractory uveitis with intravenous immunoglobulin

James (Jim) Rosenbaum, Roger K. George, Cathy Gordon

Research output: Contribution to journalArticle

49 Citations (Scopus)

Abstract

PURPOSE: To study the treatment of uveitis that has not responded to immunosuppressive medication. Intravenous immunoglobulin (IVIg) effectively treats a variety of autoimmune diseases, but it has not been adequately studied in the treatment of uveitis. METHODS: The trial included patients who satisfied criteria that included noninfectious uveitis, active inflammatory disease, and a failure to respond adequately to immunosuppressive medication. We treated two patients with IVIg (0.5 gm/day, 3 days/mo initial dosage) as a pilot study and then treated an additional eight patients with a similar dosage as part of a formal but uncontrolled protocol. RESULTS: Patients on the protocol have been followed for a median of 11 months and have received a median of 7.5 treatment cycles. Five of 10 patients have had a clinically important and sustained improvement in visual acuity, and two of eight protocol patients have markedly reduced their immunosuppressive medication. CONCLUSIONS: Intravenous immunoglobulin can benefit some patients with uveitis that is otherwise refractory to immunosuppressive therapy. Although our preliminary experience is encouraging, the use of IVIg for uveitis should be limited because of cost, toxicity, the requirement for repeated administration, and the absence of controlled trials that demonstrate efficacy.

Original languageEnglish (US)
Pages (from-to)545-549
Number of pages5
JournalAmerican Journal of Ophthalmology
Volume127
Issue number5
DOIs
StatePublished - 1999

Fingerprint

Intravenous Immunoglobulins
Uveitis
Immunosuppressive Agents
Therapeutics
Autoimmune Diseases
Visual Acuity
Costs and Cost Analysis

ASJC Scopus subject areas

  • Ophthalmology

Cite this

The treatment of refractory uveitis with intravenous immunoglobulin. / Rosenbaum, James (Jim); George, Roger K.; Gordon, Cathy.

In: American Journal of Ophthalmology, Vol. 127, No. 5, 1999, p. 545-549.

Research output: Contribution to journalArticle

Rosenbaum, James (Jim) ; George, Roger K. ; Gordon, Cathy. / The treatment of refractory uveitis with intravenous immunoglobulin. In: American Journal of Ophthalmology. 1999 ; Vol. 127, No. 5. pp. 545-549.
@article{0b0e686a565b42ebae75f72f9b6a486b,
title = "The treatment of refractory uveitis with intravenous immunoglobulin",
abstract = "PURPOSE: To study the treatment of uveitis that has not responded to immunosuppressive medication. Intravenous immunoglobulin (IVIg) effectively treats a variety of autoimmune diseases, but it has not been adequately studied in the treatment of uveitis. METHODS: The trial included patients who satisfied criteria that included noninfectious uveitis, active inflammatory disease, and a failure to respond adequately to immunosuppressive medication. We treated two patients with IVIg (0.5 gm/day, 3 days/mo initial dosage) as a pilot study and then treated an additional eight patients with a similar dosage as part of a formal but uncontrolled protocol. RESULTS: Patients on the protocol have been followed for a median of 11 months and have received a median of 7.5 treatment cycles. Five of 10 patients have had a clinically important and sustained improvement in visual acuity, and two of eight protocol patients have markedly reduced their immunosuppressive medication. CONCLUSIONS: Intravenous immunoglobulin can benefit some patients with uveitis that is otherwise refractory to immunosuppressive therapy. Although our preliminary experience is encouraging, the use of IVIg for uveitis should be limited because of cost, toxicity, the requirement for repeated administration, and the absence of controlled trials that demonstrate efficacy.",
author = "Rosenbaum, {James (Jim)} and George, {Roger K.} and Cathy Gordon",
year = "1999",
doi = "10.1016/S0002-9394(99)00029-X",
language = "English (US)",
volume = "127",
pages = "545--549",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "5",

}

TY - JOUR

T1 - The treatment of refractory uveitis with intravenous immunoglobulin

AU - Rosenbaum, James (Jim)

AU - George, Roger K.

AU - Gordon, Cathy

PY - 1999

Y1 - 1999

N2 - PURPOSE: To study the treatment of uveitis that has not responded to immunosuppressive medication. Intravenous immunoglobulin (IVIg) effectively treats a variety of autoimmune diseases, but it has not been adequately studied in the treatment of uveitis. METHODS: The trial included patients who satisfied criteria that included noninfectious uveitis, active inflammatory disease, and a failure to respond adequately to immunosuppressive medication. We treated two patients with IVIg (0.5 gm/day, 3 days/mo initial dosage) as a pilot study and then treated an additional eight patients with a similar dosage as part of a formal but uncontrolled protocol. RESULTS: Patients on the protocol have been followed for a median of 11 months and have received a median of 7.5 treatment cycles. Five of 10 patients have had a clinically important and sustained improvement in visual acuity, and two of eight protocol patients have markedly reduced their immunosuppressive medication. CONCLUSIONS: Intravenous immunoglobulin can benefit some patients with uveitis that is otherwise refractory to immunosuppressive therapy. Although our preliminary experience is encouraging, the use of IVIg for uveitis should be limited because of cost, toxicity, the requirement for repeated administration, and the absence of controlled trials that demonstrate efficacy.

AB - PURPOSE: To study the treatment of uveitis that has not responded to immunosuppressive medication. Intravenous immunoglobulin (IVIg) effectively treats a variety of autoimmune diseases, but it has not been adequately studied in the treatment of uveitis. METHODS: The trial included patients who satisfied criteria that included noninfectious uveitis, active inflammatory disease, and a failure to respond adequately to immunosuppressive medication. We treated two patients with IVIg (0.5 gm/day, 3 days/mo initial dosage) as a pilot study and then treated an additional eight patients with a similar dosage as part of a formal but uncontrolled protocol. RESULTS: Patients on the protocol have been followed for a median of 11 months and have received a median of 7.5 treatment cycles. Five of 10 patients have had a clinically important and sustained improvement in visual acuity, and two of eight protocol patients have markedly reduced their immunosuppressive medication. CONCLUSIONS: Intravenous immunoglobulin can benefit some patients with uveitis that is otherwise refractory to immunosuppressive therapy. Although our preliminary experience is encouraging, the use of IVIg for uveitis should be limited because of cost, toxicity, the requirement for repeated administration, and the absence of controlled trials that demonstrate efficacy.

UR - http://www.scopus.com/inward/record.url?scp=0032909082&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032909082&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(99)00029-X

DO - 10.1016/S0002-9394(99)00029-X

M3 - Article

C2 - 10334347

AN - SCOPUS:0032909082

VL - 127

SP - 545

EP - 549

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 5

ER -